RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA

被引:1975
作者
MACDONALD, DR
CASCINO, TL
SCHOLD, SC
CAIRNCROSS, JG
机构
[1] LONDON REG CANC CTR,790 COMMISSIONERS RD E,LONDON N6A 4L6,ONTARIO,CANADA
[2] UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON N6A 3K7,ONTARIO,CANADA
[3] UNIV WESTERN ONTARIO,DEPT ONCOL,LONDON N6A 3K7,ONTARIO,CANADA
[4] MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905
[5] DUKE UNIV,MED CTR,DEPT MED NEUROL,DURHAM,NC 27710
关键词
D O I
10.1200/JCO.1990.8.7.1277
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We suggest 'new' response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.
引用
收藏
页码:1277 / 1280
页数:4
相关论文
共 14 条
[1]   POST-SURGICAL CONTRAST ENHANCEMENT MIMICKING RESIDUAL BRAIN-TUMOR [J].
CAIRNCROSS, JG ;
PEXMAN, JHW ;
RATHBONE, MP .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1985, 12 (01) :75-75
[2]   SUCCESSFUL CHEMOTHERAPY FOR RECURRENT MALIGNANT OLIGODENDROGLIOMA [J].
CAIRNCROSS, JG ;
MACDONALD, DR .
ANNALS OF NEUROLOGY, 1988, 23 (04) :360-364
[3]   STEROID-INDUCED CT CHANGES IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA [J].
CAIRNCROSS, JG ;
MACDONALD, DR ;
PEXMAN, JHW ;
IVES, FJ .
NEUROLOGY, 1988, 38 (05) :724-726
[4]  
CASCINO T L, 1988, Neurology, V38, P306
[5]   ABSENCE OF CONTRAST ENHANCEMENT ON CT BRAIN-SCANS OF PATIENTS WITH SUPRATENTORIAL MALIGNANT GLIOMAS [J].
CHAMBERLAIN, MC ;
MUROVIC, JA ;
LEVIN, VA .
NEUROLOGY, 1988, 38 (09) :1371-1374
[6]   THE ACCURACY OF VOLUMETRIC MEASUREMENT OF HIGH-GRADE GLIOMAS [J].
CHISHOLM, RA ;
STENNING, S ;
HAWKINS, TD .
CLINICAL RADIOLOGY, 1989, 40 (01) :17-21
[7]   CRITERIA FOR TERMINATION OF PHASE-II CHEMOTHERAPY FOR PATIENTS WITH PROGRESSIVE OR RECURRENT BRAIN-TUMOR [J].
FRIEDMAN, HS ;
SCHOLD, SC ;
DJANG, WT ;
KURTZBERG, J ;
LONGEE, DC ;
HALPERIN, EC ;
FALLETTA, JM ;
COLEMAN, RE ;
OAKES, WJ .
NEUROLOGY, 1989, 39 (01) :62-66
[8]  
LEFKOWITZ I, 1987, P AN M AM SOC CLIN, V6, P71
[9]   CRITERIA FOR EVALUATING PATIENTS UNDERGOING CHEMOTHERAPY FOR MALIGNANT BRAIN TUMORS [J].
LEVIN, VA ;
CRAFTS, DC ;
NORMAN, DM ;
HOFFER, PB ;
SPIRE, JP ;
WILSON, CB .
JOURNAL OF NEUROSURGERY, 1977, 47 (03) :329-335
[10]   COMPUTERIZED-TOMOGRAPHY IN THE PROGNOSIS OF MALIGNANT CEREBRAL GLIOMAS [J].
MUROVIC, J ;
TUROWSKI, K ;
WILSON, CB ;
HOSHINO, T ;
LEVIN, V .
JOURNAL OF NEUROSURGERY, 1986, 65 (06) :799-806